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Anticoagulation Management and Heparin Resistance
During Cardiopulmonary Bypass: A Survey of Society
of Cardiovascular Anesthesiologists Members
Roman M. Sniecinski, MD, MSc,* Elliott Bennett-Guerrero, MD,† and Linda Shore-Lesserson, MD‡
We surveyed Society of Cardiovascular Anesthesiologists members regarding anticoagulation
practices for cardiopulmonary bypass and attitudes on heparin resistance. Of 550 respondents
(18.5% response rate), 74.9% (95% CI, 71.3%–78.5%) used empiric weight-based dosing of
heparin, and 70.7% (95% CI, 66.9%–74.5%) targeted an activated clotting time of either 400
or 480 seconds to initiate cardiopulmonary bypass. Of note, 17.1% (95% CI, 13.9%–20.2%) of
respondents reported activated clotting time targets lower than those recommended by recent
2018 Society of Thoracic Surgeons/Society of Cardiovascular Anesthesiologists/American
Society of Extracorporeal Technology guidelines or failed to monitor heparin effects at all. When
heparin resistance was encountered, 54.2% of respondents (95% CI, 50.0%–58.4%) administered antithrombin concentrates as a first-line therapy. (Anesth Analg 2019;129:e41–4)

D

espite its longevity of use for anticoagulation during
cardiac surgery, significant variability in heparin dosing and monitoring has been reported. A 1993 survey
of members of the Society of Cardiovascular Anesthesiologists
and American Society of Extracorporeal Technology demonstrated that, although the activated clotting time was used
by 99% of respondents, acceptable values for the conduct
of cardiopulmonary bypass (CPB) ranged from 240 to 1000
seconds.1 A survey of 54 North American institutions administered in 2008 by the Duke Clinical Research Institute and
published by Lobato et al2 reported a similarly wide range of
target activated clotting times, with values of 400–480 seconds
being used by approximately 70% of respondents. Variability
in anticoagulation practices is likely the result of a gap in evidence and any formal recommendations. Only recently have
the Society of Cardiovascular Anesthesiologists, American
Society of Extracorporeal Technology, and the Society of
Thoracic Surgeons released clinical practice guidelines for
CPB anticoagulation.3
Decreased heparin responsiveness, frequently termed
“heparin resistance,” is an area that lacks consensus in either
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diagnosis or treatment. The reported incidence during CPB
use ranges from 4% to 26%4 and is highly dependent on the
initial bolus dose of heparin and the desired activated clotting
time target for CPB initiation. Therapies for heparin resistance
include antithrombin concentrates, fresh frozen plasma, and
the administration of additional heparin.4 The 2011 blood conservation guidelines from the Society of Thoracic Surgeons
and Society of Cardiovascular Anesthesiologists recommend
administration of antithrombin concentrates in preference to
fresh frozen plasma in instances of antithrombin-mediated
heparin resistance.5 However, the acceptance and impact of this
recommendation remain unknown. In the report by Lobato et
al,2 fresh frozen plasma was the predominant treatment for
heparin resistance in 85% of US and Canadian centers.2
Recently, Miles et al6 conducted a global survey of CPB
priming practices and reported that 72.7% of respondents
used an activated clotting time target between 400 and 500
seconds for initiation of CPB. That particular survey, however, asked only 1 question regarding activated clotting time
values and contained no items related to heparin dosing or
responsiveness. We conducted the present survey to describe
both (1) current practice of anticoagulation for initiation and
maintenance of CPB and (2) clinician attitudes on heparin
resistance and their current use of antithrombin concentrates.
In addition, since 2018 Society of Thoracic Surgeons/Society
of Cardiovascular Anesthesiologists/American Society of
Extracorporeal Technology CPB anticoagulation guidelines
have just been released,3 we wanted to use the collected survey data to determine what percentage of practitioners are
already compliant with these recommendations.

METHODS
Survey Creation and Validation

The authors used SurveyMonkey online software (San
Mateo, CA) to create a pilot survey, which was administered to members of the Division of Cardiothoracic
Anesthesiology at Emory University. Answers pertaining
to heparin dosing and antithrombin concentrate usage were
compared to known institutional protocols to ensure that the
survey instrument was accurately capturing actual clinical
practice. The final iteration of the survey had 20 questions
and is provided in Supplemental Digital Content 1, Survey,
www.anesthesia-analgesia.org
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http://links.lww.com/AA/C680. The survey was reviewed
and approved by the Society of Cardiovascular Anesthesio
logists’s Research Committee and the Emory School of
Medicine’s Institutional Review Board. The requirement for
written informed consent was waived by both entities.

Survey Distribution
The target population was members of the Society of
Cardiovascular Anesthesiologists at the “Active” and
“Associate” levels, representing licensed physicians
actively taking care of cardiac surgical patients. Members
at the “Fellow/Resident” and “Career Scientist” levels were
excluded. The Society of Cardiovascular Anesthesiologists
membership office distributed an electronic link to the survey to all eligible members via an initial e-mail communication on August 2, 2017. Members had approximately 2
months to complete the survey, with follow-up reminder
e-mails sent on August 24, 2017 and September 29, 2017.
The survey closed on October 1, 2017. Members were asked
to complete the survey only once.

Determination of Guideline Compliance
The recent Society of Thoracic Surgeons/Society of
Cardiovascular Anesthesiologists/American Society of
Extracorporeal Technology guidelines for CPB anticoagulation contain items related to “Heparin dosing for initiation and maintenance of CPB.”3 The recommendations state
that a clotting time should be measured and demonstrate
“adequate anticoagulation” before initiation and at regular
intervals during CPB.3 Guidance on minimal acceptable
activated clotting time values is given as either >480 or
>400 seconds when whole blood is maximally activated or
microcuvette technology is used.3 Thus, respondents who
either did not use activated clotting times or targeted activated clotting times <400 seconds either before initiation of
CPB or during CPB (survey questions 8, 9, and 11) were considered not compliant with these recommendations.

Completion Incentive
Responses were anonymous, but participants had the
option of entering an e-mail address into a random drawing for 1 of 10 Amazon gift cards valued at $125 and 1 of
5 annual memberships to the Society of Cardiovascular
Anesthesiologists (value of $270).

Responses Analyzed
Respondents who indicated on the survey that they did
not care for adult patients undergoing cardiac surgery
using CPB were excluded. Responses with identical e-mail
addresses entered for the incentive drawing were considered to be duplicates, and only the first completed survey
was used for purposes of the incentive drawing and the
analysis. Respondents who entered only demographic
information for the purposes of the incentive drawing were
not used in the analysis.

Statistical Analysis
Based on an estimated membership population of 3000, CIs
of 95%, and a sample proportion of 0.5, we calculated that
we would need 501 responses to achieve a global margin
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of error of 4%. Descriptive statistics, including frequency
tables with proportions and bar graphs, were used to summarize the data. Wald CIs for proportions were set at 95%.
Responses to individual questions that were left blank were
classified as “unknown.” All calculations were performed
using SAS software version 9.4 (SAS Institute Inc, Cary, NC).

RESULTS
The electronic link to the survey was distributed to 2972
Society of Cardiovascular Anesthesiologists members.
We received 580 responses, of which 550 were used
for analysis, giving an effective response rate of 18.5%
(Supplemental Digital Content 2, Figure 2, http://links.
lww.com/AA/C681). Respondent demographics are
provided in the Table and closely mirrored the membership composition of the Society of Cardiovascular
Anesthesiologists (Supplemental Digital Content 3, Figure
3A, http://links.lww.com/AA/C682), with 83.8% of
responses coming from North America. Responses from
all states within the United States were received, with
the exceptions of Delaware, Idaho, North Dakota, South
Dakota, and Wyoming (Supplemental Digital Content 3,
Figure 3B, http://links.lww.com/AA/C682).
Answers to specific heparin management questions are
provided in the Table. An empiric weight-based approach to
determining the pre-CPB heparin bolus was used by 74.9% of
respondents (95% CI, 71.3%–78.5%). Empiric weight-based
doses of heparin used for initiation of CPB are provided
in Figure 1A. The maximum dose of heparin that respondents would administer before initiating additional therapy to achieve a target activated clotting time is provided
in Figure 1B. Heparin was also added to the CPB circuit by
the majority of respondents (84%; 95% CI, 80.9%–87.0%).
Adequate anticoagulation was assessed by targeting a specific activated clotting time for “initiation” of CPB and “during” CPB by 84.7% (95% CI, 81.7%–87.7%) and 88.4% (95%
CI, 85.7%–91.1%) of respondents, respectively. In addition to
an activated clotting time, 13.1% (95% CI, 10.3%–15.9%) also
used a heparin level to determine adequate anticoagulation
for initiation of CPB, and 6.7% (95% CI, 4.6%–8.8%) maintained a specific heparin level during CPB.
For those respondents who used an activated clotting
time to determine adequate anticoagulation for CPB initiation, either with or without a heparin level (538 of 550), an
activated clotting time value of 480 or 400 seconds was used
by 70.7% (95% CI, 66.9%–74.5%). The full range of activated
clotting time targets for initiation and maintenance of CPB
is provided in Figure 2. Of the 550 respondents, 17.1% (95%
CI, 13.9%–20.2%) provided answers inconsistent with 2018
Society of Thoracic Surgeons/Society of Cardiovascular
Anesthesiologists/American Society of Extracorporeal
Technology guidelines regarding activated clotting time
targets for initiation and/or maintenance of CPB.
Specific answers to questions regarding heparin resistance are provided in the Table. In terms of frequency,
about half of respondents felt that they encountered it in
1%–10% of the CPB cases they performed. More clinicians
administered antithrombin concentrate as a first-line treatment (54.2%; 95% CI, 50.0%–58.5%) compared to those who
administered fresh frozen plasma as a first-line treatment
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Table. Survey Responses

Table. Continued

Demographics of Respondents
Region
United States
Canada
Europe
Australia/New Zealand
Mexico/South America
Asia
Africa/Middle East
Do you work with anesthesia residents
of fellows? (“Yes” response)
No. of CPB cases per year
≤250
251–500
501–1000
>1000

n (%)
430 (78.2)
31 (5.6)
34 (6.2)
26 (4.7)
17 (3.1)
11 (2.0)
1 (0.2)
332 (60.4)

107
152
172
119

Heparin Management

n (%)

(19.5)
(27.6)
(31.3)
(21.6)
95% CI of %

How do you determine the dose of
heparin to administer before
initiating CPB?
Empiric weight based (eg, units/kg)
412 (74.9) 71.3%–78.5%
Dose–response calculation (eg, Hepcon 135 (24.5) 20.9%–28.1%
[Medtronic, Minneapolis, MN])
Other/unknown
3 (0.5)
0%–1.2%
How do you determine an adequate
degree of anticoagulation for
initiation of CPB?
Target an activated clotting time
466 (84.7) 81.7%–87.7%
Target both an activated clotting time
72 (13.1) 10.3%–15.9%
and heparin level
Other
8 (1.5)
0.5%–2.5%
Unknown
4 (0.7)
0%–1.4%
Do you add heparin to the CPB circuit/
reservoir before initiating CPB?
Yes
No
Unknown
How do you maintain anticoagulation
during CPB (ie, after CPB is already
initiated)?
Give additional heparin to target an
activated clotting time
Give additional heparin to maintain
heparin level
Other
Unknown

462 (84) 80.9%–87.0%
71 (12.9) 10.1%–15.7%
17 (3.1)
1.6%–4.5%

486 (88.4) 85.7%–91.1%

Attitudes on Heparin Resistance
Approximately what percentage of cardiac
surgical cases using CPB do you
encounter clinically significant
heparin resistance?
<1%
1%–10%
>10%
Unknown
Assuming the desired level of
anticoagulation is not achieved with
heparin alone, what is the first action
you would take?
Administer antithrombin concentrate
Administer fresh frozen plasma
Administer an alternate anticoagulant
Initiate CPB anyway
Unknown

37 (6.7)

4.6%–8.8%

20 (3.6)
7 (1.3)

2.1%–5.2%
0.3%–2.2%

n (%)

95% CI of %

191 (34.7) 30.7%–38.7%
298 (54.2) 50.0%–58.4%
47 (8.5)
6.2%–10.9%
14 (2.5)
1.2%–3.9%

298 (54.2) 50.0%–58.4%
211 (38.4) 34.3%–42.4%
12 (2.2)
1.0%–3.4%
5 (0.9)
0.1%–1.7%
24 (4.4)
2.7%–6.1%
(Continued)
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Attitudes on Heparin Resistance
When you encounter heparin resistance,
how often do you administer
antithrombin concentrate?
Always/very often
Often/sometimes
Rarely/never
Unknown

n (%)

95% CI of %

220 (40.0) 35.9%–44.1%
112 (20.4) 17.0%–23.7%
192 (34.9) 30.9%–38.9%
26 (4.7)
2.9%–6.5%

Do you agree with the 2011 Society
of Thoracic Surgeons/Society of
Cardiovascular Anesthesiologists
Blood Conservation recommendation
regarding use of antithrombin
concentrate to treat heparin
resistance?
Yes
283 (51.5) 47.3%–55.6%
Yes, but not as a class I
89 (16.2) 13.1%–19.3%
recommendation
No
7 (1.3)
0.3%–2.2%
I am not familiar with this
145 (26.4) 22.7%–30.1%
recommendation
Unknown
26 (4.7)
2.9%–6.5%
When antithrombin concentrate is not
used in cases of heparin resistance,
the primary reason is:
Not on my hospital’s formulary
The cost is too high
I prefer to give fresh frozen plasma
Unfamiliar with antithrombin
concentrate or recommendations

76 (32.5)
74 (31.6)
44 (18.8)
40 (17.1)

26.4%–38.5%
25.6%–37.6%
13.8%–23.8%
12.2%–22.0%

Results are given as n (%) of respondents selecting a particular answer.
Abbreviation: CPB, cardiopulmonary bypass.

(38.4%; 95% CI, 34.3%–42.4%). The majority of respondents were in agreement with the 2011 Society of Thoracic
Surgeons/Society of Cardiovascular Anesthesiologists recommendation to use antithrombin concentrate, although
about one-third rarely or never utilized it in cases of heparin resistance. The primary reason antithrombin concentrates were not used in this situation was cost being too
high and antithrombin concentrates not being on the hospital formulary.

DISCUSSION
Our survey of Society of Cardiovascular Anesthesiologists
members regarding anticoagulation practices for CPB consisted mostly of clinicians in North America but included
a balanced distribution of small-, medium-, and large-volume centers, as well as a close split between programs with
and without trainees. Like the survey conducted in 2008
by Lobato et al,2 we found that empiric dosing of heparin
with activated clotting time targets of 400 or 480 seconds
is used by the majority of practitioners. Of note, however,
is that >15% of respondents reported using anticoagulation
therapy falling outside of recent 2018 Society of Thoracic
Surgeons/Society of Cardiovascular Anesthesiologists/
American Society of Extracorporeal Technology guidelines3;
it may be useful to use this number as a starting point to
gauge adoption of these recommendations. It is also interesting to note that more clinicians now use antithrombin
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Figure 1. Bar graphs of (A) percentage
of respondents indicating either empiric
weight-based dose or a calculated dose
based on heparin dose–response (HDR)
curve, which is typically administered
before the initiation of cardiopulmonary
bypass (CPB), and (B) percentage of
respondents indicating what the maximum dose of heparin they would give
before administering additional therapy
to achieve the desired level of anticoagulation for CPB. Doses are given in
U/kg. Error bars indicate Wald 95% CIs
of the proportion.
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Figure 2. Bar graph of percentage of those respondents who utilized
activated clotting times (ACTs) targeting a specific ACT value for initiation (green bars) and maintenance (red bars) of cardiopulmonary
bypass (CPB). Error bars indicate Wald 95% CIs of the proportion.

concentrate in cases of heparin resistance compared to 10
years ago. In conclusion, while anticoagulation targets for
CPB, as determined by the activated clotting time, have
remained steady over the past decade, antithrombin concentrate utilization has increased when those targets are felt
to be inadequately met. E
ACKNOWLEDGMENTS

We thank Kathryn Egan, CRN (Department of Anesthesiology,
Emory University School of Medicine, Atlanta, Georgia), for
her regulatory assistance and Francisco M. Mota Villaplana,
PharmD, MSc (Grifols, S.A., Barcelona, Spain), for his advocacy of this project.

e44   
www.anesthesia-analgesia.org

REFERENCES
1. Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology. 1999;91:1122–1151.
2. Lobato RL, Despotis GJ, Levy JH, Shore-Lesserson LJ, Carlson
MO, Bennett-Guerrero E. Anticoagulation management during
cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg. 2010;139:1665–1666.
3. Shore-Lesserson L, Baker RA, Ferraris VA, et al. The Society
of Thoracic Surgeons, The Society of Cardiovascular
Anesthesiologists, and The American Society of ExtraCorporeal
Technology: clinical practice guidelines-anticoagulation during
cardiopulmonary bypass. Anesth Analg. 2018;126:413–424.
4. Finley A, Greenberg C. Review article: heparin sensitivity and
resistance: management during cardiopulmonary bypass.
Anesth Analg. 2013;116:1210–1222.
5. Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update to the
Society of Thoracic Surgeons and the Society of Cardiovascular
Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944–982.
6. Miles LF, Coulson TG, Galhardo C, Falter F. Pump priming practices
and anticoagulation in cardiac surgery: results from the global cardiopulmonary bypass survey. Anesth Analg. 2017;125:1871–1877.

ANESTHESIA & ANALGESIA

